[go: up one dir, main page]

TR200900879A2 - Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler - Google Patents

Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler

Info

Publication number
TR200900879A2
TR200900879A2 TR2009/00879A TR200900879A TR200900879A2 TR 200900879 A2 TR200900879 A2 TR 200900879A2 TR 2009/00879 A TR2009/00879 A TR 2009/00879A TR 200900879 A TR200900879 A TR 200900879A TR 200900879 A2 TR200900879 A2 TR 200900879A2
Authority
TR
Turkey
Prior art keywords
combined
pharmaceutical compositions
dosage form
active ingredients
single dosage
Prior art date
Application number
TR2009/00879A
Other languages
English (en)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2009/00879A priority Critical patent/TR200900879A2/tr
Priority to PCT/TR2010/000025 priority patent/WO2010101537A1/en
Publication of TR200900879A2 publication Critical patent/TR200900879A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Mevcut buluş, aktif maddelerin hastanın tedaviye uyumunu ve dolayısıyla tedavinin başarısını artırmak üzere tek bir dozaj formunda kombine edildiği farmasötik bileşimlere ilişkindir.
TR2009/00879A 2009-02-05 2009-02-05 Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler TR200900879A2 (tr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TR2009/00879A TR200900879A2 (tr) 2009-02-05 2009-02-05 Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler
PCT/TR2010/000025 WO2010101537A1 (en) 2009-02-05 2010-02-02 Pharmaceutical composition of alendronate and a calcium salt combined in a single dosage form

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2009/00879A TR200900879A2 (tr) 2009-02-05 2009-02-05 Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler

Publications (1)

Publication Number Publication Date
TR200900879A2 true TR200900879A2 (tr) 2010-08-23

Family

ID=42245666

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2009/00879A TR200900879A2 (tr) 2009-02-05 2009-02-05 Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler

Country Status (2)

Country Link
TR (1) TR200900879A2 (tr)
WO (1) WO2010101537A1 (tr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170104664A (ko) * 2010-12-06 2017-09-15 에프락스 파머슈티컬즈 소시에떼 아노님 신속한 용해 특성을 구비한 안정한 발포성 비스포스포네이트 제형
US9670210B2 (en) 2014-02-13 2017-06-06 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
TWI720451B (zh) 2014-02-13 2021-03-01 美商英塞特控股公司 作為lsd1抑制劑之環丙胺
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
MX373154B (es) 2015-04-03 2020-04-22 Incyte Holdings Corp Compuestos heterocíclicos como inhibidores de demetilasa 1 específica de lisina (lsd1).
LT3334709T (lt) 2015-08-12 2025-03-10 Incyte Holdings Corporation Lsd1 inhibitoriaus druskos
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
CN116285419B (zh) * 2023-03-20 2025-08-01 贺州学院 复合表面改性剂制备低吸油值重质碳酸钙的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040188316A1 (en) * 2003-03-26 2004-09-30 The Procter & Gamble Company Kit for pharmaceutical use
WO2007031785A2 (en) * 2005-09-16 2007-03-22 Selamine Ltd Bisphosphonate formulation

Also Published As

Publication number Publication date
WO2010101537A1 (en) 2010-09-10

Similar Documents

Publication Publication Date Title
TR200900878A2 (tr) Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar
CY1118661T1 (el) Φαρμακευτικη συνθεση, φαρμακευτικη δοσολογικη μορφη, διαδικασια για την παρασκευη τους, μεθοδοι για αντιμετωπιση και χρησεις αυτων
TR200900879A2 (tr) Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
IN2012DN06720A (tr)
MX350046B (es) Tratamientos para trastornos gastrointestinales.
EA201290171A1 (ru) Вводимые перорально кортикостероидные композиции
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
HN2011003011A (es) Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas
EA201492290A1 (ru) Составы и способы для вагинальной доставки антипрогестинов
MX2011008634A (es) Derivados de aminotetralina composiciones farmaceuticas que los contienen y su uso en terapia.
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
PH12012501522A1 (en) Oral care compositions
PH12012501620A1 (en) Oral care compositions
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
TN2015000135A1 (en) Modified release formulations for oprozomib
TR201009394A2 (tr) Geliştirilmiş montelukast formülasyonları.
EA201390950A1 (ru) Гомогенные фармацевтические пероральные лекарственные формы, содержащие лерканидипин и эналаприл или их фармацетически приемлемые соли совместно с органической кислотой
TR200806300A2 (tr) Çözünürlük artırıcı farmasötlk formulasyon
TR200900880A2 (tr) Tek bir dozaj formunda kombine edilen farmasötik bileşimler.
TR200900881A2 (tr) Tadı ve kokusu maskelenmiş stabil farmasötik bileşimler
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
TR200906506A2 (tr) Telmisartan içeren katı dozaj formları.
TR201005327A2 (tr) Sinerjik farmasötik formülasyonlar.
EA201291420A1 (ru) Пероральные лекарственные формы, содержащие лерканидипин и эналаприл и их фармацевтически приемлемые соли